Company news

Actinogen Medical Limited news in 2024

Actinogen Medical Limited's news releases, calls and decks from 2024, newest first.

View company

ACW randomizes first US participant in Alzheimers trial

December 8, 2024

Actinogen receives $9.0 million R&D tax incentive rebate

November 11, 2024

ACW September 2024 quarterly activity report & Appendix 4C

October 29, 2024

$3.0 million share purchase plan closes 1.3x oversubscribed

October 10, 2024

ACW $11.1m capital raising to accelerate Alzheimers trial

September 18, 2024

Pause in Trading

September 16, 2024

ACW FY2024 results, advancing into late-stage trials

August 29, 2024

ACW Appendix 4E and 2024 Annual Report

August 29, 2024

ACW updated depression trial results and implications

August 25, 2024

ACW XanaCIDD phase 2a trial topline results

August 11, 2024

ACW June 2024 quarterly activity report & Appendix 4C

July 21, 2024

ACW XanaCIDD depression trial results expected early August

July 1, 2024

Positive Xanamem biomarker trial published in Jnl Alz Dis

June 26, 2024

ACW Oversubscribed $3.9 million entitlement offer completed

June 4, 2024

Actinogen entitlement offer closed and oversubscribed

May 29, 2024

Prospectus - Non-renounceable Entitlement Offer

May 6, 2024

Actinogen announces capital raising of up to $8.9 million

May 3, 2024

ACW March 2024 quarterly activity report & Appendix 4C

April 30, 2024

ACW completes cognition & depression phase 2 trial enrolment

April 21, 2024

First patient treated in ACW XanaMIA ph 2b Alzheimers trial

April 14, 2024

Actinogen HY2024 financial results two key phase 2 trial

February 25, 2024

Actinogen HY2024 financial report and Appendix 4D

February 25, 2024

Response to ASX Aware Query

February 19, 2024

Actinogen awarded UK Innovation Passport for Xanamem

February 15, 2024

ACW December 2023 quarterly activity report & Appendix 4C

January 29, 2024

Decks in 2024